跳到正文
FDA 官方药品与生物制品信息·· 19 天前AI 评分53

FDA于2026年6月11日举办以患者为中心的口服仿制药生物等效性挑战研讨会

Advancing Generic Drug Development: Bioequivalence Challenges for Patient-Centric Oral Formulations - 06/11/2026

AI 导读

FDA于2026年6月11日举办以患者为中心的口服仿制药生物等效性挑战研讨会,页面汇集各讲题录音与幻灯片。议题覆盖咀嚼片、口崩片、颗粒/微丸、混悬剂及舌下/颊部制剂,并涉及PBPK建模和儿科制剂开发。会议设两场问答,讲者来自CDER仿制药办公室等。

正文 · 原文

Webcast | Virtual

Event Title

Advancing Generic Drug Development: Bioequivalence Challenges for Patient-Centric Oral Formulations

June 11, 2026

Date:
June 11, 2026

Visit CDER Small Business and Industry Assistance (SBIA) Homepage



Topics & Presentations

Speakers

Session 1

Current Landscape of Patient-Centric Formulations in Generic Drug Development

Recording and Slides

Karen Li, PharmD
Pharmacologist
Division of Therapeutic Performance II (DTP II)
Office of Research and Standards (ORS)
Office of Generic Drugs (OGD) | CDER

Developing Pediatric Formulations: Regulatory Considerations

Recording and Slides

Vilayat Sayeed, PhD
Division Director
Division of Product Quality Assessment II
Office of Product Quality Assessment I (OPQA I)
Office of Pharmaceutical Quality (OPQ) | CDER

Suitability Petitions: An Avenue for Patient-Centric Formulations

Recording and Slides

Andrew Fine, PharmD
Associate Director for Regulatory Affairs
Office of Safety and Clinical Evaluation OGD | CDER

Extrapolation Using PBPK Modeling to Support the Development of Pediatric Products

Recording and Slides

Fang Wu, PhD
Senior Pharmacologist
Division of Quantitative Methods and Modeling
ORS | OGD | CDER

Questions and Answer Session 1

Recording

Moderator
Jihong Shon, MD, PhD
Associate Director for Clinical Safety
DTP II | ORS | OGD | CDER

Panelists
Karen Li
Vilayat Sayeed
Andrew Fine
Fang Wu
and joined by
Meirong Hao, PhD
Lead Pharmacologist
Division of Bioequivalence III
Office of Bioequivalence (OB) | OGD | CDER

Session 2

Bioequivalence Strategies for Chewable Tablets: Regulatory Considerations

Recording and Slides

Hye Lim Lim, PharmD
Visiting Associate
DTP II | ORS | OGD | CDER

Granules and Pellets PSGs

Recording and Slides

Wen Cheng Yang, MD
Senior Staff Fellow
DTP II | ORS | OGD | CDER

Dose Selection Consideration for Pharmacokinetic Bioequivalence Studies of Oral Suspension Products

Recording and Slides

Duyen Nguyen, PharmD
Staff Fellow
DTP II | ORS | OGD | CDER

Scientific and Regulatory Considerations for Sublingual Products

Recording and Slides

Wei-Jhe Sun, PhD
Senior Staff Fellow
DTP II | ORS | OGD | CDER

Bioequivalence Strategies for Orally Disintegrating Tablets: Regulatory Considerations

Recording and Slides

Heather Boyce, PhD
Lead Pharmacokineticist
DTP II | ORS | OGD | CDER

In Vitro Feeding Tube Studies: Scientific and Regulatory Perspectives

Recording and Slides

Geng Tian, PhD
Research Officer
Division of Pharmaceutical Quality Research VI
Office of Pharmaceutical Quality Research
OPQ | CDER

Shamema Nasrin, PhD
Research Scientist
DTP II | ORS | OGD | CDER

Questions and Answer Session 2

Recording

Moderator
Jihong Shon

Panelists
Hye Lim Lim
Wen Cheng Yang
Duyen Nguyen
Wei-Jhe Sun
Heather Boyce
Shamema Nasrin
Geng Tian
and joined by
Xiaojian Jiang, PhD
Deputy Division Director
Division of Bioequivalence II
OB | OGD | CDER

Closing Remarks

Recording

Myong-Jin Kim, PharmD
Division Director
DTP II | ORS | OGD | CDER

About this Event (Hosted by CDER SBIA)

The field of patient-specialized oral drug formulations continues to evolve, presenting unique bioequivalence (BE) challenges that require innovative regulatory approaches. This workshop is designed to facilitate discussions about the latest advancements and regulatory considerations in the evolving field of patient-centric (including pediatric) generic oral products, addressing product development and regulatory assessment challenges for these important medicines.

Attendees will gain valuable insights into the intricacies of developing generic versions of specialized oral formulations across diverse areas. The scope of discussions will include chewable tablets, orally disintegrating tablets, pellet/granule formulations, suspension products, and sublingual/buccal formulations. This workshop will also address challenges for the development and assessment of generic pediatric-specific formulations designed to meet the unique needs of patient populations with swallowability challenges.

Through a series of expert-led presentations and Q&A sessions, participants will have the opportunity to hear from and pose questions to experts from FDA, to help deepen their understanding of current best practices, challenges and opportunities, regulatory expectations, and emerging trends. Specifically, the workshop will cover critical areas such as regulatory strategies for patient-centric formulations, formulation-specific development issues, regulatory strategies for pediatric formulations, and innovative BE approaches including physiologically based pharmacokinetic (PBPK) modeling to support generic pediatric product development. These topics reflect some of the most challenging issues facing patient-centric oral generic drug development, and the workshop will facilitate a discussion of the scientific and regulatory innovations being deployed to overcome these challenges.

Don't miss this unique opportunity to learn how to improve your generic drug development!

Intended Audience

Scientists, researchers, current and prospective generic drug applicants, and regulatory affairs professionals who work on or have an interest in the development of oral generic drugs.

Topics Covered

  • Common regulatory challenges of patient-centric oral formulations
  • Up-to-date formulation-specific regulatory strategies and best practices to support the product development and BE evaluation (including feeding tube studies and BE study dose selection) of various patient-centric oral formulations, including chewable tablets, pellets/granules, sublingual/buccal products, orally disintegrating tablets, and suspensions.
  • Known issues and practical strategies for the development of generic oral pediatric formulations

Learning Objectives

  • Stay up to date with the latest advancements in science, research, FDA guidance recommendations, and regulatory perspectives related to relevant oral generic drug products
  • Recognize and explain how the FDA's GDUFA-funded research can be leveraged to support and inform generic drug development
  • Learn how to utilize various strategies and methodologies to facilitate efficient generic drug development

Resources

来源:FDA 官方药品与生物制品信息 · fda.gov